• Chronic Lymphocytic Leukemia (CLL) Monitoring, MRD Detection, Blood
  • Cancer Antigen (CA) 27- 29
  • Vanillylmandelic Acid (VMA) and Homovanillic Acid (HVA), Random, Urine
  • Calcitonin (Thyrocalcitonin)
  • Beta-amyloid (Aβ1-40 and Aβ1-42), Plasma
  • Triazolam, Urine
  • Hemosiderin Stain, Urine
  • Brugada Syndrome Multi-Gene Panel, NGS
  • SelectMDx for Prostate Cancer
  • Histoplasma capsulatum Antibody, CSF
  • LDS
  • Sign up
  • Log in
  • LDS
  • /Medical Tests
  • /BCR-ABL1 Mutation Analysis for Tyrosine Kinase Inhibitor Resistance
  • All
  • Diseases
  • Overview
  • Clinical Utility
  • Interpretation
  • Reference Ranges
  • Methodology
  • Specimen Collection
  • Additional Testing
  • Turnaround Time
  • CPT
  • LOINC
  • ICD10
  • Additional ICD10
  • References
  • All
  • Diseases
  • Overview
  • Clinical Utility
  • Interpretation
  • Reference Ranges
  • Methodology
  • Specimen Collection
  • Additional Testing
  • Turnaround Time
  • CPT
  • LOINC
  • ICD10
  • Additional ICD10
  • References

BCR-ABL1 Mutation Analysis for Tyrosine Kinase Inhibitor Resistance
Medical Test

Clinical Utility
Access to BCR-ABL1 Mutation Analysis for Tyrosine Kinase Inhibitor Resistance is restricted.
Loading...